Notizia - Recent Pharma, Healthcare and Biotech Happenings

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more by offering 40% more shares.  The company plans to use the funds raised to address the unmet needs in the Alzheimer’s disease market and is developing ANVS-401, which can inhibit the production of neurotoxic proteins, a potential cure for the disease. Moreover, the company is also planning to treat Down syndrome, traumatic brain injury, Parkinson’s disease, frontotemporal dementia, and glaucoma.  The company has become the latest biotech developer to sell its shares even before d...